These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 34348634)

  • 1. Pharmacological Basis of Breast Cancer Resistance to Therapies - An Overview.
    Crucitta S; Cucchiara F; Sciandra F; Cerbioni A; Diodati L; Rafaniello C; Capuano A; Fontana A; Fogli S; Danesi R; Re MD
    Anticancer Agents Med Chem; 2022; 22(4):760-774. PubMed ID: 34348634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacotherapeutic options for patients with refractory breast cancer.
    Fedele P; Ciccarese M; Surico G; Cinieri S
    Expert Opin Pharmacother; 2019 May; 20(7):851-861. PubMed ID: 30730767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy for Breast Cancer Treatment: Current Evidence and Therapeutic Options.
    Singh K; Yadav D; Jain M; Singh PK; Jin JO
    Endocr Metab Immune Disord Drug Targets; 2022; 22(2):212-224. PubMed ID: 33902424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estrogen Receptor-Positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance.
    Brufsky AM; Dickler MN
    Oncologist; 2018 May; 23(5):528-539. PubMed ID: 29352052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The therapeutic potential of immunotherapy in the treatment of breast cancer: Rational strategies and recent progress.
    Javid H; Attarian F; Saadatmand T; Rezagholinejad N; Mehri A; Amiri H; Karimi-Shahri M
    J Cell Biochem; 2023 Apr; 124(4):477-494. PubMed ID: 36966454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triple-negative breast cancer.
    Stockmans G; Deraedt K; Wildiers H; Moerman P; Paridaens R
    Curr Opin Oncol; 2008 Nov; 20(6):614-20. PubMed ID: 18841042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
    Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
    Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current Molecular Combination Therapies Used for the Treatment of Breast Cancer.
    Wang Y; Minden A
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic significance of hormone receptor positivity in patients with HER-2 positive breast cancer.
    Kolarova I; Vanasek J; Odrazka K; Melichar B; Ryska A; Petera J; Vosmik M; Dolezel M
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2019 Dec; 163(4):285-292. PubMed ID: 31831888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer.
    Ribas R; Pancholi S; Rani A; Schuster E; Guest SK; Nikitorowicz-Buniak J; Simigdala N; Thornhill A; Avogadri-Connors F; Cutler RE; Lalani AS; Dowsett M; Johnston SR; Martin LA
    Breast Cancer Res; 2018 Jun; 20(1):44. PubMed ID: 29880014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance to endocrine therapy in HR + and/or HER2 + breast cancer: the most promising predictive biomarkers.
    Miranda F; Prazeres H; Mendes F; Martins D; Schmitt F
    Mol Biol Rep; 2022 Jan; 49(1):717-733. PubMed ID: 34739691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular classification of infiltrating breast cancer: toward personalized therapy.
    Trop I; LeBlanc SM; David J; Lalonde L; Tran-Thanh D; Labelle M; El Khoury MM
    Radiographics; 2014; 34(5):1178-95. PubMed ID: 25208275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The next generation personalized models to screen hidden layers of breast cancer tumorigenicity.
    Afzali F; Akbari P; Naderi-Manesh H; Gardaneh M
    Breast Cancer Res Treat; 2019 Jun; 175(2):277-286. PubMed ID: 30810866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted therapy for breast cancer and molecular mechanisms of resistance to treatment.
    Gu G; Dustin D; Fuqua SA
    Curr Opin Pharmacol; 2016 Dec; 31():97-103. PubMed ID: 27883943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Global View of Candidate Therapeutic Target Genes in Hormone-Responsive Breast Cancer.
    Salvati A; Gigantino V; Nassa G; Mirici Cappa V; Ventola GM; Cracas DGC; Mastrocinque R; Rizzo F; Tarallo R; Weisz A; Giurato G
    Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32517194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic progress and challenges for triple negative breast cancer: targeted therapy and immunotherapy.
    Yang R; Li Y; Wang H; Qin T; Yin X; Ma X
    Mol Biomed; 2022 Mar; 3(1):8. PubMed ID: 35243562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triple-negative breast cancer: current state of the art.
    Rastelli F; Biancanelli S; Falzetta A; Martignetti A; Casi C; Bascioni R; Giustini L; Crispino S
    Tumori; 2010; 96(6):875-88. PubMed ID: 21388048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changing Treatment Paradigms in Metastatic Breast Cancer: Lessons Learned.
    Santa-Maria CA; Gradishar WJ
    JAMA Oncol; 2015 Jul; 1(4):528-34; quiz 549. PubMed ID: 26181262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy for Breast Cancer is Finally at the Doorstep: Immunotherapy in Breast Cancer.
    De La Cruz LM; Czerniecki BJ
    Ann Surg Oncol; 2018 Oct; 25(10):2852-2857. PubMed ID: 30014455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.